

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No : L24239MH1987PLC043662

November 6, 2018

To,

BSE Ltd.,
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street - Fort,
Mumbai – 400 001



Office Address:
Factory Address:

**NATIONAL COMPANY LAW TRIBUNAL,
MUMBAI BENCH
IN THE PETITION NO. 3715 OF 2018
APPLICATION NO. 621 OF 2018**

Companies Act, 2013;
AND
232 read with section 230 and other applicable
Companies Act, 2013 and other rules framed
AND
the Merger of Industeel Plates India Private
Company") with Smaks Trading Private
Company") and their respective
Limited,
for the provisions of
registered office at
Point, Mumbai -
...Second Petitioner Company

HEARING OF PETITION

232 of the Companies Act, 2013 for an order
larger by Absorption of Industeel Plates India
Company") with Smaks Trading Private
Company") and their respective Shareholders, was
Companies on 5th November, 2018 and the said
the Mumbai Bench of National Company Law
ber, 2018.

ting or opposing the said Petition should send to
ice of his/ her intention, signed by him/her or his/
me and address, so as to reach the Petitioners'
ays before the date fixed for the hearing of the
to oppose the petition, the grounds of opposition
all be furnished with such notice.

furnished by the undersigned to any person
of the prescribed charges for the same.

Sd/-
Hemant Sethi & Co
Advocates for the Petitioners
1602, Nav Parmanu, Behind Amar Cinema,
Chembur Mumbai - 400071

SWASTIKA INVESTMART LIMITED

Regd. off.: Flat No. 18, 2nd Floor, North Wing, Madhaveshwar Co-op Hsg Society Ltd., Madh
11/12, S.V. Road, Andheri W, Mumbai, Maharashtra - 400058
Email: info@swastika.co.in, Website: www.swastika.co.in, CIN: L65910MH1992PLC067052, Phone No.

NOTICE

NOTICE is hereby given that pursuant to the Regulation 29 read with Regulation
(Listing Obligations and Disclosure Requirements) Regulation 2015, the meeting
of Directors of the Company scheduled to be held on Tuesday, 13th November
consider and approve the un-audited Financial Results of the Company for the qu
as half year ended on 30th September, 2018 along with other routine businesses.
This intimation is also available on the website of the company (www.swastika
the website of the Stock Exchange (www.bseindia.com).

By order of
For Swastika Investmart
Shikha B

Date: 05/11/2018

Place: Mumbai

Company Secretary & Compliance

Bright Brothers Limited

CIN: L25209MH1946PLC005056

Regd. Office: 610-611; Nirman Kendra, Famous Studio Lane,
Dr. E. Moses Road, Mahalaxmi, Mumbai 400 011 • Tel.: 91 22 249
• E-mail: invcom@brightbrothers.co.in • Website: www.brightbroth

Pursuant to Regulation 29 read with Regulation 47 of the Secu
Exchange Board of India (Listing Obligations and D
Requirements) Regulations, 2015, notice is hereby given that
of the Board of Directors of the Company is scheduled to be
Wednesday, 14th November, 2018, inter alia, to consider and
the unaudited financial results of the Company for the quar
months ended on 30th September, 2018.

The said Notice may be accessed on the Company's
www.brightbrothers.co.in and may also be accessed on the v
Stock Exchange at www.bseindia.com.

For Bright Bro

Place: Mumbai

Date: 6th November, 2018 Company Secretary & Compliance

Sonali



FREDUN PHARMACEUTICALS LTD.

CIN : L24239MH1987PLC043662

Registered Office: 26, Manoj Industrial Premises, G.D. Ambekar Marg, Wadala, Mumbai - 400 031
Phone Number: +91 22 4031 8111 Fax: +91 22 4031 8133
Email: business@fredungroup.com | Website: www.fredungroup.com

Extract Of Unaudited Financial Results For The Quarter & Half Year Ended September 30, 2018

(Rs. in Lacs)

Sr. No.	Particulars	Quarter Ended		Half Year ended	Year ended
		Sept 2018 (Unaudited)	Sept 2017 (Unaudited)	Sept 2018 (Unaudited)	March 2018 (Audited)
1.	Total Income from Operations	2210.05	1549.69	3861.78	5971.08
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	226.40	50.64	163.45	264.173.
	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	226.40	50.57	163.45	264.17
4.	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	226.40	43.57	163.45	175.09
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	226.40	43.57	163.45	175.09
6.	Equity Share Capital	401.18	294.72	401.18	344.72
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	1871.54
8.	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) -				
1.	Basic:	5.64	1.47	4.07	5.07
2.	Diluted:	5.64	1.47	4.07	5.07

Note:

a) The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites of the BSE Ltd. at www.bseindia.com and of the Company at www.fredungroup.com

b) # - Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.

For Fredun Pharmaceuticals Limited

Sd/-

Fredun Medhora

Managing Director & Compliance Officer

Place : Mumbai

Date : November 5, 2018

CITIBA
Gorego
Notice/
Citibank
for an a
which t

Sr.
No.
1. 1.
2. 1.
Flo
De
Chi
Am
3. 1.
4. 1.
5. 1.
6. 1.
Up
Bh
8. M
9. 1.
No
Pat
Ant
11.
12.
13.
14.
(Ap
E E
Pro
15.
16.
17.
18.
19.
Flat